NCT02752126View on ClinicalTrials.gov

A Randomized Phase III Study of Palliative Radiation of Advanced Central Tumors With Intentional Avoidance of the Esophagus

NACompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

August 1, 2020

Study Completion Date

September 1, 2020

Conditions
Non-Small Cell Lung Cancer
Interventions
RADIATION

Conventional radiotherapy

Patients will receive standard palliative radiation in dose of 30Gy in 10 fractions, or 20Gy in 5 fractions.

RADIATION

Esophageal-Sparing Intensity-Modulated Radiotherapy

Patients will receive esophageal-sparing intensity-modulated radiotherapy, of 30Gy in 10 fractions or 20Gy in 5 fractions.

Trial Locations (7)

T6G 1Z2

Cross Cancer Institute, Edmonton

B3H 1V7

Atlantic Clinical Cancer Centre, Halifax

N2G 1G3

Grand River Regional Cancer Centre/Grand River Hospital, Kitchener

N6A 4L6

London Regional Cancer Program, London

L5M 2N1

Trillium Health Partners - Credit Valley Hospital, Mississauga

M5G 2M9

Princess Margaret Hospital/ University Health Network, Toronto

H3H 2R9

McGill University Health Centre, Montreal

All Listed Sponsors
lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT02752126 - A Randomized Phase III Study of Palliative Radiation of Advanced Central Tumors With Intentional Avoidance of the Esophagus | Biotech Hunter | Biotech Hunter